Alvogen, Inc., a prominent player in the global pharmaceutical industry, is headquartered in the United States. Founded in 2009, the company has rapidly expanded its operations across key regions, including North America, Europe, and Asia. Alvogen focuses on developing and manufacturing generic and specialty pharmaceuticals, with a strong emphasis on high-quality, affordable medications. The company is recognised for its innovative approach to drug development, particularly in the areas of oncology, respiratory, and central nervous system therapies. Alvogen's commitment to quality and efficiency has positioned it as a competitive force in the market, achieving significant milestones such as the successful launch of numerous generic products. With a robust portfolio and a dedication to improving patient access to essential medicines, Alvogen continues to make strides in the pharmaceutical landscape.
Alvogen, Inc.'s reported carbon emissions
In 2024, Alvogen, Inc. reported total carbon emissions of approximately 411.9 million kg CO2e. This figure includes Scope 1 emissions of about 13.7 million kg CO2e, Scope 2 emissions of approximately 34.6 million kg CO2e, and significant Scope 3 emissions totalling around 384.1 million kg CO2e. The Scope 3 emissions breakdown reveals key contributors such as purchased goods and services (approximately 308.1 million kg CO2e) and upstream transportation and distribution (about 19.3 million kg CO2e). Comparatively, in 2023, Alvogen's total emissions were approximately 81.4 million kg CO2e, with Scope 1 emissions at about 15.0 million kg CO2e and Scope 3 emissions around 52.8 million kg CO2e. This indicates a substantial increase in emissions from 2023 to 2024. Alvogen has not publicly committed to specific reduction targets or initiatives, as indicated by the absence of documented reduction targets or climate pledges. The company operates as a current subsidiary of a larger corporate family, inheriting emissions data from its parent organisation, which is Alvogen, Inc. This cascading of data reflects the company's commitment to transparency in its environmental impact reporting. Overall, Alvogen's emissions data highlights the significant challenges it faces in managing its carbon footprint, particularly within its Scope 3 emissions, which represent the majority of its total emissions.
Unlock Detailed Emission Data
Access structured emission data, company specific emission factors, and source documents.
How Carbon Intensive is Alvogen, Inc.'s Industry?
How Carbon Intensive is Alvogen, Inc.'s Location?
Alvogen, Inc.'s Scope 3 Categories Breakdown
Alvogen, Inc.'s reported Scope 3 emissions increased by 627% last year and increased by approximately 761% since 2021. The vast majority of their reported carbon footprint comes from their upstream supply chain categories, with "Purchased Goods and Services" being the largest emissions source at 80% of total reported Scope 3 emissions.
Top Scope 3 Categories
Alvogen, Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Alvogen, Inc. has established climate goals through participation in recognized frameworks and target-setting initiatives. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
Usage Policy
You're welcome to quote or reference data from this page, but please include a visible link back to this URL.
Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbon data come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Curious To See Your Top Supplier’s Emissions? Book A Demo For A Pilot Project.
Book a demo for your project.